Market Update (NASDAQ:GILD): European Commission Grants Marketing Authorization for Gilead’s Harvoni®▼ (Ledipasvir/Sofosbuvir), the First Single Tablet Regimen to Treat the Majority of Chronic Hepatitis C Patients With Genotype 1 and 4

[Business Wire] – Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for Harvoni® , the first once-daily single tablet regimen to treat the majority of chronic hepatitis C . . . → Read More: Market Update (NASDAQ:GILD): European Commission Grants Marketing Authorization for Gilead’s Harvoni®▼ (Ledipasvir/Sofosbuvir), the First Single Tablet Regimen to Treat the Majority of Chronic Hepatitis C Patients With Genotype 1 and 4 Similar Articles: Company Update: Gilead Sciences Inc (NASDAQ:GILD) – U.S. FDA approves Gilead’s $94,500 hepatitis C drug Market Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead signs hepatitis C pact to cut drug cost for poor Stock Update (NASDAQ:GILD): UK cost body backs pricey Gilead hepatitis pill for some patients